Compare INAB & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INAB | CDLX |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.1M |
| IPO Year | 2020 | 2018 |
| Metric | INAB | CDLX |
|---|---|---|
| Price | $0.75 | $1.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $7.00 | $4.43 |
| AVG Volume (30 Days) | ★ 69.2K | 60.7K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $233,273,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.53 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.55 |
| 52 Week High | $2.73 | $6.40 |
| Indicator | INAB | CDLX |
|---|---|---|
| Relative Strength Index (RSI) | 32.88 | 23.58 |
| Support Level | N/A | $0.85 |
| Resistance Level | $1.50 | $1.16 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 9.62 | 9.57 |
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.